PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?

Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA damage repair (DDR) genes. <i>BRCA1/2</i> mutations occur at 1–7% across biliary tract cancers (BTCs), but a b...

Full description

Bibliographic Details
Main Authors: Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Veronica Mollica, Ilaria Maggio, Marzia Deserti, Simona Tavolari, Giovanni Brandi
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Medicines
Subjects:
biliary tract cancer
cholangiocarcinoma
PARP
BRCA
olaparib
rucaparib
Online Access:https://www.mdpi.com/2305-6320/7/9/54

Internet

https://www.mdpi.com/2305-6320/7/9/54

Similar Items